Search for: "Sanofi"
Results 1 - 20
of 1,186
Sort by Relevance
|
Sort by Date
26 Apr 2024, 12:41 pm
Sanofi, 598 U.S. 594 (2023) and was struck by the Supreme Court’s statement that its 19th Century decision of Wood v. [read post]
23 Apr 2024, 10:28 am
Sanofi. [read post]
14 Apr 2024, 9:05 pm
., a mid-cap oncology firm that was resisting one hostile bidder (Sanofi S.A.) and encouraging another firm (Pfizer) to outbid Sanofi. [read post]
7 Apr 2024, 9:59 pm
Sanofi Pasteur Inc. [read post]
3 Apr 2024, 8:18 pm
Sanofi Pasteur Inc. [read post]
28 Mar 2024, 8:07 pm
Sanofi Pasteur Inc. [read post]
25 Mar 2024, 9:53 pm
Sanofi Pasteur Inc. [read post]
12 Mar 2024, 9:13 pm
Sanofi Pasteur Inc., affirming the Patent Trial and Appeal Board's (PTAB) determination that all claims of U.S. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
6 Mar 2024, 10:15 am
Sanofi Pasteur Inc. affirming lower rulings by the Patent Trial and Appeal Board (PTAB) that invalidated Pfizer’s patent claims and denied motions to amend (MTA). [read post]
6 Mar 2024, 10:15 am
Sanofi Pasteur Inc. affirming lower rulings by the Patent Trial and Appeal Board (PTAB) that invalidated Pfizer’s patent claims and denied motions to amend (MTA). [read post]
5 Mar 2024, 10:55 am
., Adventist Health System, a 340B covered entity, is suing pharmaceutical manufacturers AbbVie, AstraZeneca, Novartis, Sanofi, and Sandoz alleging that the manufacturers caused violations of the False Claims Act and various state anti-fraud laws when calculating the 340B price for drugs with price increases that outpaced inflation. [read post]
5 Mar 2024, 10:23 am
Sanofi Opinion. [read post]
23 Jan 2024, 9:01 pm
2023 delivered a banner year for investor recoveries, as the $7.9 billion[1] in settlement funds across the globe was the highest total in the last five years. [read post]
21 Jan 2024, 9:01 pm
Many of these cases have important implications for near-term merger reviews and enforcement actions including Sanofi/Maze Therapeutics (abandoned), a challenge to the license of a phase 2-ready pharmaceutical, traditionally viewed as likely too nascent to present a competitive issue; Amgen/Horizon Therapeutics (consent decree), a challenge focused on the parties’ ability to entrench the existing monopoly position of a non-overlap product; and Anesthesia Partners (ongoing), as… [read post]
